The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

Kowdley reviews open-label extension data for biochemical response, ALP normalization, and pruritus improvement from the phase 3 ELATIVE study.

At NASPGHAN 2024, HCPLive spoke with Duncan about how treating infants who appear to have reflux may actually result in greater repeat hospital visits.

Findings from the open-label extension of the ELATIVE study suggest sustained safety and efficacy for up to 3 years, with improvements in itch and sleep.

This segment of Han’s interview featured a discussion of the safety profile of dupilumab and ensifentrine, as well as other details in the GOLD 2025 Report.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Vivek Kaul, MD, discusses the various options available for colorectal cancer screening, providing an overview of stool-based tests, blood-based tests, colonoscopy, and emerging screening methods.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Diabetes was associated with an increased risk of liver transplant or death and with liver-specific events in patients with PBC.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.

GERD diagnoses in BRUE infants were linked to frequent acid suppression use and repeat hospital visits, according to a study presented at NASPGHAN 2024.

However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.

In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.

Liver transplant waitlisting after a weekend was associated with higher 1-year post-transplant mortality compared with patients listed on a weekday.

Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.

More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.

A nasal spray form of bumetanide reduced tissue swelling from heart failure as effectively as the oral and intravenous formulations.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

HCPLive spoke with Lat at NASPGHAN 2024 about how for communities with high H. pylori prevalence, it is best to test for H. pylori before a colonoscopy.

GLP-1RA use was associated with a reduced risk of adverse liver outcomes in patients with alcohol-associated liver disease and type 2 diabetes.